CANSINOBIO Reports 27.40% Nine-Month Revenue Growth; Bottom-Line Impacted by VAT Change and Higher Expenses

Bulletin Express10-27

CanSino Biologics Inc. (CANSINOBIO) released its unaudited results for the nine months ended 30 September 2026.

Revenue Trends • Operating revenue reached RMB 882.31 million, up 27.40% year-on-year (YoY), driven by an expanding commercial vaccine portfolio and growing overseas sales. • Third-quarter (Q3) revenue rose 7.17% YoY to RMB 332.48 million.

Profitability • Profit before tax for the nine-month period increased to RMB 23.01 million, a 171.06% YoY surge, helped by tighter cost control and efficiency gains. • Net profit attributable to shareholders stood at RMB 16.29 million, up 12.82% YoY; Q3 net profit fell 39.08% YoY to RMB 17.01 million. • Excluding non-recurring items, the company recorded a nine-month loss of RMB 44.98 million, yet Q3 core profit improved 66.56% YoY to RMB 5.07 million.

Key Cost Items • Selling expenses rose to RMB 307.97 million (+11.09% YoY) as the group expanded market penetration. • Research and development spend totaled RMB 259.54 million, representing 29.42% of revenue and a 5.33% YoY decline in absolute terms. • Share-based payment expenses and foreign-exchange losses weighed on Q3 earnings, while other income linked to international R&D funding fell YoY.

Cash Flow and Balance Sheet • Operating cash outflow was RMB 23.86 million versus an inflow of RMB 33.49 million a year earlier, reflecting higher spending on channel development and academic promotion. • Total assets decreased 4.63% from year-end 2025 to RMB 6.85 billion, while shareholders’ equity edged up 1.09% to RMB 5.01 billion. • Cash and cash equivalents at period-end were RMB 1.13 billion.

Regulatory Impact A Value-Added Tax policy shift effective 1 January 2026 lifted the VAT rate on domestic vaccine sales from 3% to 13%. The transition allowed input-tax deductions but exerted pressure on margins during the reporting period.

Shareholder Structure HKSCC Nominees Limited remained the largest shareholder with 97.86 million shares (39.61%). Five founders and related entities collectively held over 31% of share capital.

Audit Status The figures are prepared under Chinese Accounting Standards and have not been audited.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment